Agenda
7.20 Check In & Morning Coffee
Chair’s Opening Remarks
Speaker
-
Daniel Smith
Senior Vice President - Ribonucleic Acid Biochemistry & Chemistry Manufacturing & Controls Development - Tech Innovations
Visions for the Future of mRNA & Beyond: The Leadership Perspective
Speaker
-
Chloe Nelson
CSO COO - Prime Marketing
Current Cancer Vaccine Strategies Including Initial Phase 1 Study Data of CVGBM, an Off-the-Shelf Cancer Vaccine in Glioblastoma
Cancer vaccines based on mRNA technologies have shown encouraging clinical data over the last couple of years Showcasing current strategies to develop cancer vaccines focus on either personalized cancer vaccines or off-the-shelf cancer vaccines Presenting CVGBM, an off-the-shelf cancer vaccine, that demonstrated encouraging immunogenicity in a phase 1 study in patients with GBM after tumor…
Speaker
-
Olivia Johnson
Chief Executive Officer & Head of Translational Research & Alliance Management - People First Co.
10:15 Morning Break & Speed Networking
TRACK A: DISCOVERY & PRE-CLINICAL DEVELOPMENT
Chair: Nigel Horscroft, Chief Technology Officer, Stealth Mode mRNA Biotech
Speaker
-
Grace Ramirez
Senior Manager - Wordsmith Agency
Deciphering a Regulatory Framework & Guidance for Future mRNA Platforms to Harmonise Clinical & Manufacturing Development
Speaker
-
Scarlett Scott
Health Innovation Lead - Viral Media Co.
The Value of a Harmonised Regulatory Framework for mRNA Medicines
mRNA platform technology approaches supported by regulatory provisions Diverse regulatory understanding of platform technology from various perspectives Examples of platform technology – platform technology approaches today and in the future
Speaker
-
Amelia Clark
Head of Regulatory Policy Europe - ClientCare Inc.
Harnessing In Vivo Therapeutic Antibody Production Enabled by mRNA-LNP Technology
Outlining novel mRNA-LNP platform for mRNA therapeutic antibody production Exploring therapeutic antibody potential from discovery to pre-clinical development Overcoming key challenges of in vivo protein expression for successful translation of mRNA-based therapeutics
Speaker
-
Grace Ramirez
Senior Manager - Wordsmith Agency
Swiss Regulatory Aspects & Evaluation for mRNABased Vaccines & Therapeutic Pathways to Approval
Exploring harmonisation regulatory challenges and expectations for new mRNA drugs applications and documentation Delineating the mRNA platform definition for vaccine, therapeutic and broader applications Highlighting regulatory progress in personalised mRNA cancer vaccines and manufacturing considerations
Speaker
-
James Williams
Founder & Chief Executive Officer - Green Finance
Session Reserved for: Tebu Bio
Speaker
-
Lily Baker
Senior Product Manager - Advanced Therapeutics OEM - Talent Works
Session Reserved for: Arcalis
Speaker
-
David Adams
Director Alliance Management - Cloud Solutions
12.55 Lunch Break & Networking
Turbocharging new mRNA-LNP Programs to Expand Therapeutic Potential with European Research Initiatives & Collaborations
Forging New Commercial Partnerships to Ensure Smooth Transfer into Trials & Manufacturing at Scale
REGeRNA Project: Identifying & Developing mRNAEncoded Proteins Towards Novel Therapeutics for Cardiac Tissue Regeneration
Establishing the need for new treatments of heart failure Deciphering a rationale for an mRNA-based strategy for reinducing proliferation of cardiomyocytes Showcasing first results and remaining challenges
Speaker
-
Ella Allen
Professor - Thoracic & Cardiovascular Surgery - Digital Growth
Multidimensional Characterisation of RNA-Based Vaccines & Therapies
Evaluate potency through the identification of ribosome stalls that reduce protein production Examine purity by discovering the sequences and structures that lead to dsRNA by-products Measure safety through studies of off-target changes in transcription and translation
4.00 Afternoon Break & Poster Session
As the landscape of innovation that is supercharging the next wave of efficacious mRNA vaccines and therapeutics, it is more important than ever to collaborate and learn for the growth of this field. Join our dedicated poster session to share your latest data and get the first look into what your peers are working on!
Advancing RNA Therapeutics Development: Novel Reagents for DNA Template Production by Rolling Circle Amplification
The rolling circle amplification (RCA) is an isothermal amplification technique that shows promise for generating DNA template for in vitro transcription (IVT) reaction used in therapeutic RNA production. Compared to using bacterial plasmids as DNA templates, RCA offers several advantages as speed, simplicity and safety For mRNA therapeutics development the AOF (animal origin free) reagents…
Speaker
-
Lily Baker
Senior Product Manager - Advanced Therapeutics OEM - Talent Works
Panel Discussion – A European Industry & Regulatory Perspective on the Development & Approval of mRNA Medicines
Uncovering how regulatory provisions can support mRNA medicines’ approval Reducing the regulatory approval timeline through platform technology approaches Moving towards a harmonized approach for mRNA medicines for the benefit of patients
Speakers
-
Amelia Clark
Head of Regulatory Policy Europe - ClientCare Inc. -
Ava Martinez
Vice President Global Regulatory Affairs & Pre-Clinical - Storyline Media